Aldeyra Stock Plummets 71% After FDA Rejects Lead Drug; Law Firm Launches Investigation

Aldeyra Therapeutics ($ALDX) shares collapsed 70.7% on March 17, 2026, following a devastating regulatory setback that threatens the company's core business strategy. The Rosen Law Firm has initiated a securities investigation into potential shareholder claims against the NASDAQ-listed biopharmaceutical firm after the FDA issued a Complete Response Letter rejecting the company's application for reproxalap, its flagship treatment for dry eye disease.

The regulatory rejection represents a critical inflection point for Aldeyra, a company that has bet heavily on reproxalap's commercial potential. The FDA's determination that the company failed to demonstrate sufficient efficacy evidence in treating dry eye disease—a massive market opportunity affecting millions of Americans—has fundamentally altered investor sentiment and the firm's near-term financial outlook.

The Regulatory Blow and Its Scale

The Complete Response Letter from the FDA constitutes one of the most significant setbacks a clinical-stage biopharmaceutical company can experience. Rather than granting approval, the agency indicated that Aldeyra's submitted data did not meet the agency's efficacy threshold for reproxalap as a dry eye disease therapeutic.

Key implications of this rejection include:

• Immediate capital impact: The 70.7% single-day stock decline erased substantial shareholder value and likely constrains the company's ability to raise capital through equity markets
• Timeline disruption: Reproxalap will not reach patients on the expected timeline, pushing back potential revenue generation indefinitely
• Clinical uncertainty: The FDA's rejection suggests the clinical data package was insufficient, raising questions about whether additional trials can adequately address the agency's concerns
• Dry eye disease market: This sector represents a multi-billion-dollar addressable market, making the lost opportunity particularly acute

The magnitude of the stock decline reflects investors' assessment that reproxalap was material to Aldeyra's value proposition and that alternative pathways forward may be limited or uncertain.

Market Context: Biotech Volatility and Regulatory Risk

The Aldeyra situation exemplifies the extreme risk inherent in clinical-stage biopharmaceutical investments, where binary regulatory outcomes can destroy shareholder capital nearly overnight. The broader biotech sector routinely experiences such volatility, though moves of this magnitude typically indicate market consensus that a company's prospects have fundamentally deteriorated.

Dry eye disease represents an attractive therapeutic market due to its prevalence and chronic nature, with existing treatments often inadequate. Several competitors are pursuing treatments in this space, but Aldeyra's reproxalap was positioned as a potentially differentiated option. The FDA's rejection suggests the clinical evidence did not support meaningful advantages over existing therapies or that safety or tolerability concerns emerged.

The Rosen Law Firm's investigation—which also encompasses DNOW Inc. ($DNOW) and Gartner, Inc. ($GARTNER)—indicates legal counsel's assessment that shareholders may have grounds for securities claims. Investigations of this nature typically focus on whether company management made misleading statements about clinical prospects, regulatory pathway confidence, or financial condition prior to the adverse announcement.

Investor Implications and Shareholder Concerns

For shareholders holding ALDX, the implications are severe:

Valuation destruction: A 70%+ decline in a single trading session suggests the market had substantially priced reproxalap's approval into the stock. The loss of this revenue stream leaves limited visibility into near-term profitability.

Capital position: Aldeyra must now assess whether it has sufficient cash runway to fund operations and pursue alternative programs. Biotech companies often maintain limited capital reserves relative to burn rates, making post-rejection capital raises extremely difficult and dilutive.

Pipeline assessment: Investors will scrutinize whether Aldeyra has other programs with clinical or commercial potential, or whether reproxalap was the company's sole meaningful asset.

Legal liability: The Rosen Law Firm's investigation suggests potential securities class action exposure, which could create additional financial liabilities beyond market valuation losses.

For the broader biotech investment community, the Aldeyra situation reinforces the binary nature of regulatory risk. Even programs that advance through Phase III trials can face unexpected FDA rejection, highlighting the importance of portfolio diversification and conservative position sizing in clinical-stage companies.

Forward-Looking Uncertainty

Aldeyra Therapeutics now faces critical strategic decisions. Management must determine whether to appeal the Complete Response Letter with additional data, pursue a substantially modified regulatory pathway, or redirect resources toward alternative programs. Each option carries significant uncertainty and capital requirements.

The severity of the stock decline suggests minimal market confidence in near-term recovery prospects. Investors will monitor the company's next regulatory communications and cash position disclosures closely. The Rosen Law Firm's investigation may also create a period of legal uncertainty that further pressures the stock and complicates capital-raising efforts.

For shareholders who purchased ALDX based on reproxalap's clinical potential, the March 17 FDA rejection represents a catastrophic outcome. The legal investigation offers a potential avenue for recourse, though securities litigation typically recovers only a fraction of shareholder losses. The case underscores why biopharmaceutical investing demands rigorous diligence, diversification, and realistic assessment of regulatory pathway risks.